EXACT Therapeutics publishes shareholder information regarding the delisting

Oslo, Norway, 4 September 2026. EXACT Therapeutics AS ("EXACT" or the "Company") has today published a shareholder information page on its website in connection with the upcoming delisting of the Company's shares from Euronext Growth Oslo: www.exact-tx.com/shareholder-info

The page contains practical information regarding the delisting process, key dates, shareholder communication and frequently asked questions. The information document is attached to this announcement. The shares of EXACT will be removed from trading on Euronext Growth, Oslo as of 12 October 2026. The last day of trading will be 9 October 2026. For further information, please contact: John M. Edminson Chief Financial Officer EXACT Therapeutics AS john.edminson@exact-tx.com

About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are currently traded on Euronext Growth Oslo (EXTX). An application for delisting of the shares has been approved by Oslo Stock Exchange, and last day of trading is 9 October, 2026. Further information may be found here: www.exact-tx.com